Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Rivero, Antonio"" wg kryterium: Autor


Tytuł :
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.
Autorzy :
Esteban R; Hospital Universitario Vall d'Hebron and CIBERehd del Instituto Carlos III, Barcelona, Spain. Electronic address: .
Pineda JA; Unit of Infectious Diseases and Microbiology, Hospital Universitario Virgen de Valme, Sevilla, Spain.
Calleja JL; Liver Unit, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, and Universidad Autónoma de Madrid, Madrid, Spain, and CIBERehd.
Casado M; Complejo Hospitalario Torrecárdenas, Almeria, Spain.
Rodríguez M; Hospital Universitario Central de Asturias, Oviedo, Spain.
Turnes J; Gastroenterology and Hepatology Department, Complejo Hospitalario Universitario de Pontevedra and IISGS, Pontevedra, Spain.
Morano Amado LE; Unit of Infectious Diseases, University Hospital Alvaro Cunqueiro, Institute of Health Research Galicia Sur, Vigo, Spain.
Morillas RM; Hospital Universitari Germans Trias i Pujol, Badalona, Spain, and CIBERehd.
Forns X; Liver Unit, Hospital Clínic Barcelona, and University of Barcelona, and IDIBAPS, and CIBERehd.
Pascasio Acevedo JM; Clinical Management Unit of Digestive Diseases, IBIS, CIBERehd, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Andrade RJ; Unidad de Gestión Clínica de Enfermedades Digestivas, Hospital Universitario Virgen de la Victoria, Universidad de Málaga, and IBIMA, and CIBERehd.
Rivero A; Hospital Universitario Reina Sofia/IMIBIC/UCO, Cordoba, Spain.
Carrión JA; Liver Section, Gastroenterology Department, Hospital del Mar, Universitat Autònoma de Barcelona, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
Lens S; Liver Unit, Hospital Clínic Barcelona, and University of Barcelona, and IDIBAPS, and CIBERehd.
Riveiro-Barciela M; Liver Unit Department of Internal Medicine, Hospital Universitari Vall d'Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain, and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
McNabb B; Gilead Sciences, Inc, Foster City, California.
Zhang G; Gilead Sciences, Inc, Foster City, California.
Camus G; Gilead Sciences, Inc, Foster City, California.
Stamm LM; Gilead Sciences, Inc, Foster City, California.
Brainard DM; Gilead Sciences, Inc, Foster City, California.
Subramanian GM; Gilead Sciences, Inc, Foster City, California.
Buti M; Hospital Universitario Vall d'Hebron and CIBERehd del Instituto Carlos III, Barcelona, Spain.
Pokaż więcej
Źródło :
Gastroenterology [Gastroenterology] 2018 Oct; Vol. 155 (4), pp. 1120-1127.e4. Date of Electronic Publication: 2018 Jun 27.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
Carbamates/*therapeutic use
Hepacivirus/*drug effects
Hepacivirus/*genetics
Hepatitis C/*drug therapy
Heterocyclic Compounds, 4 or More Rings/*therapeutic use
Liver Cirrhosis/*drug therapy
Ribavirin/*therapeutic use
Sofosbuvir/*therapeutic use
Antiviral Agents/adverse effects ; Carbamates/adverse effects ; Drug Combinations ; Drug Resistance, Bacterial/genetics ; Female ; Genotype ; Hepacivirus/pathogenicity ; Hepatitis C/complications ; Hepatitis C/diagnosis ; Hepatitis C/virology ; Heterocyclic Compounds, 4 or More Rings/adverse effects ; Humans ; Liver Cirrhosis/diagnosis ; Liver Cirrhosis/virology ; Male ; Middle Aged ; RNA, Viral/blood ; RNA, Viral/genetics ; Ribavirin/adverse effects ; Sofosbuvir/adverse effects ; Spain ; Sustained Virologic Response ; Time Factors ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study.
Autorzy :
Sulkowski MS; Divisions of Infectious Diseases and Gastroenterology/Hepatology, Johns Hopkins Hospital, The Johns Hopkins University School of Medicine , Baltimore, MD, USA. .
Fessel WJ; Kaiser Permanente San Francisco Medical Center, San Francisco, CA, USA.
Lazzarin A; Unit of Infectious Diseases, Clinica Malattie Infettive, Institute of Hospitalisation and Scientific Care, Milan, Italy.
Berenguer J; Unidad de Enfermedades Infecciosas/VIH (4100), Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Zakharova N; St Petersburg AIDS Center, SPT AIDS C 179A OBVODNIY CANAL, Saint Petersburg, Russian Federation.
Cheinquer H; Servico De Gastroentereologia, Hospital De Clinicas De Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil.
Côté P; Clinique Medicale Du Quartier Latin, Montreal, QC, Canada.
Dieterich D; Institute for Liver Disease, Mount Sinai School of Medicine, New York, NY, USA.
Gadano A; Hospital Italiano De Buenos Aires, Buenos Aires, Argentina.
Matthews G; St Vincent's Hospital (NSW), Darlinghurst, NSW, Australia.
Molina JM; Hopital Saint Louis, Paris, France.
Moreno C; Hospital Erasme, Brussels, Belgium.
Pineda JA; Infectious Diseases and Microbiology Unit, Hospital Universitario de Valme, Seville, Spain.
Pulido F; Hospital Universitario 12 De Octubre, Madrid, Spain.
Rivero A; Hospital Universitario Reina Sofia, Cordoba, Spain.
Rockstroh J; Universitaetsklinikum Bonn, Medizinische Klinik, Bonn, Germany.
Hernandez D; Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA.
McPhee F; Department of Virology Discovery Biology, Bristol-Myers Squibb Research and Development, Wallingford, CT, USA.
Eley T; Bristol-Myers Squibb, Princeton, NJ, USA.
Liu Z; Bristol-Myers Squibb, Hopewell, Pennington, NJ, USA.
Mendez P; Bristol-Myers Squibb, Princeton, NJ, USA.
Hughes E; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Noviello S; Bristol-Myers Squibb, Lawrenceville, NJ, USA.
Ackerman P; Bristol-Myers Squibb, Wallingford, CT, USA.
Pokaż więcej
Źródło :
Hepatology international [Hepatol Int] 2017 Mar; Vol. 11 (2), pp. 188-198. Date of Electronic Publication: 2017 Feb 16.
Typ publikacji :
Clinical Trial, Phase III; Journal Article
MeSH Terms :
Antiviral Agents/*therapeutic use
Coinfection/*drug therapy
HIV Infections/*complications
Hepatitis C, Chronic/*complications
Imidazoles/*therapeutic use
Interferon-alpha/*therapeutic use
Polyethylene Glycols/*therapeutic use
Ribavirin/*therapeutic use
Adult ; Aged ; Antiviral Agents/administration & dosage ; Antiviral Agents/adverse effects ; Coinfection/virology ; Drug Therapy, Combination ; Female ; HIV Infections/drug therapy ; Hepacivirus/drug effects ; Hepacivirus/genetics ; Hepatitis C, Chronic/drug therapy ; Humans ; Imidazoles/administration & dosage ; Imidazoles/adverse effects ; Interferon-alpha/administration & dosage ; Interferon-alpha/adverse effects ; Male ; Middle Aged ; Polyethylene Glycols/administration & dosage ; Polyethylene Glycols/adverse effects ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/adverse effects ; Recombinant Proteins/therapeutic use ; Ribavirin/administration & dosage ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
HCV viral decline at week 2 of Peg-IFN-alpha-2a/RBV therapy as a predictive tool for tailoring treatment in HIV/HCV genotype 1 co-infected patients.
Autorzy :
Rivero-Juarez A; Unidad de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
López-Cortés LF; Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Camacho A; Unidad de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
Torres-Cornejo A; Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Gordon A; Unidad de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
Ruiz-Valderas R; Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Torre-Cisneros J; Unidad de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
Pineda JA; Unidad de Enfermedades Infecciosas y Microbiología Clínica, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Seville, Spain.
Viciana P; Unidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
Rivero A; Unidad de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2014 Jun 19; Vol. 9 (6), pp. e99468. Date of Electronic Publication: 2014 Jun 19 (Print Publication: 2014).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Coinfection/*drug therapy
HIV Infections/*drug therapy
Hepatitis C/*drug therapy
Interferon-alpha/*administration & dosage
Polyethylene Glycols/*administration & dosage
Ribavirin/*administration & dosage
Adult ; Antiviral Agents/administration & dosage ; Coinfection/virology ; Female ; Genotype ; HIV Infections/pathology ; HIV Infections/virology ; Hepacivirus/drug effects ; Hepatitis C/pathology ; Hepatitis C/virology ; Humans ; Male ; Middle Aged ; Recombinant Proteins/administration & dosage ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy.
Autorzy :
Rivero-Juarez A; Unit of Infectious Diseases, Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, Cordoba, Spain.
Neukam K; Unit of Infectious Diseases and Microbiology, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Seville 41014, Spain.
Labarga P; Department of Infectious Diseases, Hospital Carlos III, Madrid 28029, Spain.
Camacho A; Unit of Infectious Diseases, Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, Cordoba, Spain.
Macias J; Unit of Infectious Diseases and Microbiology, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Seville 41014, Spain.
Barreiro P; Department of Infectious Diseases, Hospital Carlos III, Madrid 28029, Spain.
Torre-Cisneros J; Unit of Infectious Diseases, Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, Cordoba, Spain.
Pineda JA; Department of Infectious Diseases, Hospital Carlos III, Madrid 28029, Spain.
Soriano V; Unit of Infectious Diseases and Microbiology, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario de Valme, Seville 41014, Spain.
Rivero A; Unit of Infectious Diseases, Instituto Maimonides de Investigación Biomedica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, Cordoba, Spain. Electronic address: .
Pokaż więcej
Źródło :
The Journal of infection [J Infect] 2014 Apr; Vol. 68 (4), pp. 372-7. Date of Electronic Publication: 2013 Nov 22.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Viral Load*
Coinfection/*drug therapy
HIV Infections/*complications
Hepacivirus/*isolation & purification
Hepatitis C, Chronic/*drug therapy
Interferons/*therapeutic use
Ribavirin/*therapeutic use
Adult ; Female ; Hepatitis C, Chronic/complications ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.
Autorzy :
Rivero-Juarez A; Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba, Hospital Universitario Reina Sofia de Cordoba.
López-Cortés LF
Camacho A
Mira JA
Téllez F
Marquez M
Merino D
Pineda JA
Rivero A
Pokaż więcej
Corporate Authors :
Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR), part of the Sociedad Andaluza de Enfermedades Infecciosas
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2014 Jan; Vol. 58 (1), pp. 130-3. Date of Electronic Publication: 2013 Sep 24.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Viral Load*
Antiviral Agents/*therapeutic use
HIV Infections/*complications
Hepacivirus/*isolation & purification
Hepatitis C, Chronic/*complications
Interferon-alpha/*therapeutic use
Polyethylene Glycols/*therapeutic use
Ribavirin/*therapeutic use
Adult ; Female ; Genotype ; Hepacivirus/classification ; Hepacivirus/genetics ; Hepatitis C, Chronic/drug therapy ; Humans ; Male ; Middle Aged ; Recombinant Proteins/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Atazanavir-based therapy with pegylated interferon and ribavirin for patients with hepatitis C and HIV.
Autorzy :
Rivero-Juarez A; Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain.
Lopez-Cortes LF; Infectious Diseases, Microbiology and Preventive Medicine Unit, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocio, Consejo Superior de Investigaciones Científicas, Universidad de Sevilla, Seville, Spain.
Girón-Gonzalez JA; Infectious Diseases Unit, Hospital Universitario Puerta del Mar, Cádiz, Spain.
Pineda JA; Infectious Diseases and Microbiology Unit, Instituto de Biomedicina de Sevilla, Hospital Universitario de Valme, Seville, Spain.
Rivero A; Infectious Diseases Unit, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain. Electronic address: .
Pokaż więcej
Corporate Authors :
Grupo Andaluz para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas
Źródło :
The Lancet. Infectious diseases [Lancet Infect Dis] 2014 Jan; Vol. 14 (1), pp. 13-14.
Typ publikacji :
Letter; Comment
MeSH Terms :
Antiviral Agents/*administration & dosage
HIV Infections/*complications
Hepatitis C, Chronic/*complications
Hepatitis C, Chronic/*drug therapy
Interferon-alpha/*administration & dosage
Polyethylene Glycols/*administration & dosage
Proline/*analogs & derivatives
Ribavirin/*administration & dosage
Female ; Humans ; Male
Opinia redakcyjna
Tytuł :
Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection.
Autorzy :
Neukam K; aUnit of Infectious Diseases and Microbiology, Hospital Universitario de Valme bInstituto de Biomedicina de Sevilla (IBiS), Seville cImmunogenetics Unit, Faculty of Sciences, Universidad de Jaén, Jaen dUnit of Infectious Diseases, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Cordoba eDepartment of Infectious Diseases, Hospital Carlos III, Madrid fUnit of Infectious Diseases, Hospital Juan Ramón Jiménez. Huelva, Spain.
Caruz A
Rivero-Juárez A
Barreiro P
Merino D
Real LM
Herrero R
Camacho A
Soriano V
Di Lello FA
Macías J
Rivero A
Pineda JA
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2013 Nov 13; Vol. 27 (17), pp. 2715-24.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Polymorphism, Single Nucleotide*
Antiviral Agents/*administration & dosage
Hepatitis C/*drug therapy
Interferons/*administration & dosage
Interleukins/*genetics
Ribavirin/*administration & dosage
Adult ; Cohort Studies ; Female ; Genotype ; Humans ; Male ; Prognosis ; Prospective Studies ; Spain ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Sustained virological response to pegylated interferon plus ribavirin leads to normalization of liver stiffness in hepatitis C virus-infected patients.
Autorzy :
Macías J; Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario de Valme, Sevilla, Spain.
Rivero A
Cifuentes C
Camacho A
Neukam K
Rivero-Juárez A
Mira JA
Torre-Cisneros J
Gómez-Mateos J
Pineda JA
Pokaż więcej
Źródło :
Enfermedades infecciosas y microbiologia clinica [Enferm Infecc Microbiol Clin] 2013 Aug-Sep; Vol. 31 (7), pp. 424-9. Date of Electronic Publication: 2013 Feb 28.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Elasticity Imaging Techniques*
Antiviral Agents/*administration & dosage
Hepatitis C, Chronic/*diagnostic imaging
Hepatitis C, Chronic/*drug therapy
Interferon-alpha/*administration & dosage
Polyethylene Glycols/*administration & dosage
Ribavirin/*administration & dosage
Adult ; Aged ; Drug Therapy, Combination ; Female ; Follow-Up Studies ; Hepatitis C, Chronic/complications ; Hepatitis C, Chronic/virology ; Humans ; Liver Cirrhosis/diagnostic imaging ; Liver Cirrhosis/virology ; Male ; Middle Aged ; Prospective Studies ; Recombinant Proteins/administration & dosage ; Reference Values ; Treatment Outcome
Czasopismo naukowe
Tytuł :
The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
Autorzy :
Rivero-Juarez A; aUnidad de Enfermedades Infecciosas, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Hospital Universitario Reina Sofia, Cordoba bUnidad Clínica de Enfermedades Infecciosas, Microbiología y Medicina Preventiva, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville cUnidad de Inmunogenética, Faculty of Sciences, Universidad de Jaén, Jaén, Spain.
Lopez-Cortes LF
Camacho A
Caruz A
Torres-Cornejo A
Martinez-Dueñas L
Ruiz-Valderas R
Torre-Cisneros J
Gutierrez-Valencia A
Rivero A
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2013 Jul 31; Vol. 27 (12), pp. 1941-7.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Viral Load*
HIV Infections/*complications
Hepacivirus/*classification
Hepatitis C/*complications
Interferon-alpha/*therapeutic use
Interleukins/*genetics
Polyethylene Glycols/*therapeutic use
Ribavirin/*therapeutic use
Adult ; Antiviral Agents/therapeutic use ; Female ; Genotype ; HIV Infections/drug therapy ; Hepacivirus/genetics ; Hepacivirus/isolation & purification ; Hepatitis C/drug therapy ; Hepatitis C/virology ; Humans ; Interferons ; Male ; Middle Aged ; Recombinant Proteins/therapeutic use
Czasopismo naukowe
Tytuł :
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response.
Autorzy :
Neukam K; Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Avenida de Bellavista S/N, Seville, Spain.
Barreiro P
Rivero-Juárez A
Caruz A
Mira JA
Camacho A
Macías J
Rivero A
Soriano V
Pineda JA
Pokaż więcej
Źródło :
The Journal of infection [J Infect] 2013 Jul; Vol. 67 (1), pp. 59-64. Date of Electronic Publication: 2013 Mar 28.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
Hepatitis, Chronic/*drug therapy
Interferon-alpha/*therapeutic use
Interleukins/*genetics
Polyethylene Glycols/*therapeutic use
Ribavirin/*therapeutic use
Adult ; Cohort Studies ; Drug Therapy, Combination/methods ; Female ; Genotype ; Humans ; Interferon alpha-2 ; Interferons ; Male ; Middle Aged ; Prospective Studies ; Recombinant Proteins/therapeutic use ; Spain ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial.
Autorzy :
Sulkowski M; Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. />Pol S
Mallolas J
Fainboim H
Cooper C
Slim J
Rivero A
Mak C
Thompson S
Howe AY
Wenning L
Sklar P
Wahl J
Greaves W
Pokaż więcej
Corporate Authors :
P05411 study investigators
Źródło :
The Lancet. Infectious diseases [Lancet Infect Dis] 2013 Jul; Vol. 13 (7), pp. 597-605. Date of Electronic Publication: 2013 Jun 12.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*administration & dosage
HIV Infections/*complications
Hepatitis C, Chronic/*complications
Hepatitis C, Chronic/*drug therapy
Interferon-alpha/*administration & dosage
Polyethylene Glycols/*administration & dosage
Proline/*analogs & derivatives
Ribavirin/*administration & dosage
Adolescent ; Adult ; Aged ; Antiviral Agents/adverse effects ; Double-Blind Method ; Drug Therapy, Combination/adverse effects ; Drug Therapy, Combination/methods ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Drug-Related Side Effects and Adverse Reactions/pathology ; Female ; Genotype ; HIV Infections/virology ; HIV-1/isolation & purification ; Hepacivirus/classification ; Hepacivirus/genetics ; Hepacivirus/isolation & purification ; Humans ; Interferon alpha-2 ; Interferon-alpha/adverse effects ; Male ; Middle Aged ; Placebos/administration & dosage ; Placebos/adverse effects ; Polyethylene Glycols/adverse effects ; Proline/administration & dosage ; RNA, Viral/blood ; Recombinant Proteins/administration & dosage ; Recombinant Proteins/adverse effects ; Ribavirin/adverse effects ; Treatment Outcome ; Viral Load ; Young Adult
Czasopismo naukowe
Tytuł :
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Autorzy :
Mira JA; Unidad de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario de Valme, Avenida de Bellavista s/n, 41014 Sevilla, Spain.
Rivero-Juárez A
López-Cortés LF
Girón-González JA
Téllez F
de los Santos-Gil I
Macías J
Merino D
Márquez M
Ríos-Villegas MJ
Gea I
Merchante N
Rivero A
Torres-Cornejo A
Pineda JA
Pokaż więcej
Corporate Authors :
Grupo Andaluz para el Estudio de las Hepatitis Víricas de la Sociedad Andaluza de Enfermedades Infecciosas
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2013 Jun; Vol. 56 (11), pp. 1646-53. Date of Electronic Publication: 2013 Feb 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
HIV Infections/*virology
Hepatitis C/*drug therapy
Interferon-alpha/*therapeutic use
Liver Cirrhosis/*virology
Polyethylene Glycols/*therapeutic use
Ribavirin/*therapeutic use
Adult ; Female ; Hepacivirus/drug effects ; Hepatitis C/virology ; Humans ; Kaplan-Meier Estimate ; Liver Failure/virology ; Male ; Middle Aged ; Multivariate Analysis ; Prospective Studies ; Recombinant Proteins/therapeutic use
Czasopismo naukowe
Tytuł :
Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
Autorzy :
Mira JA; Unidad de Enfermedades Infecciosas y Microbiología Clínica, Spain.
García-Rey S
Rivero A
de los Santos-Gil I
López-Cortés LF
Girón-González JA
Téllez F
Márquez M
Merino D
Ríos-Villegas MJ
Macías J
Rivero-Juárez A
Pineda JA
Pokaż więcej
Źródło :
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2012 Dec; Vol. 55 (12), pp. 1719-26. Date of Electronic Publication: 2012 Sep 05.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
HIV Infections/*drug therapy
Hepatitis C/*drug therapy
Interferon-alpha/*therapeutic use
Liver Cirrhosis/*drug therapy
Polyethylene Glycols/*therapeutic use
Ribavirin/*therapeutic use
Adult ; Female ; HIV Infections/virology ; Hepacivirus/drug effects ; Hepacivirus/genetics ; Hepatitis C/virology ; Humans ; Interferon alpha-2 ; Liver Cirrhosis/virology ; Male ; Middle Aged ; Multivariate Analysis ; Odds Ratio ; Prospective Studies ; RNA, Viral/blood ; Recombinant Proteins/therapeutic use ; Statistics, Nonparametric ; Viral Load/drug effects
Czasopismo naukowe
Tytuł :
Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.
Autorzy :
Mira JA; Unidad de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario de Valme, Seville, Spain.
Rivero A
de Los Santos-Gil I
López-Cortés LF
Girón-González JA
Márquez M
Merino D
del Mar Viloria M
Téllez F
Ríos-Villegas MJ
Omar M
Rivero-Juárez A
Macías J
Pineda JA
Pokaż więcej
Corporate Authors :
Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)
Źródło :
AIDS (London, England) [AIDS] 2012 Aug 24; Vol. 26 (13), pp. 1721-4.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*pharmacology
HIV Infections/*drug therapy
Hepacivirus/*drug effects
Hepatitis C/*drug therapy
Interferon-alpha/*pharmacology
Polyethylene Glycols/*pharmacology
Ribavirin/*pharmacology
Coinfection ; Drug Therapy, Combination ; Female ; Genotype ; Hepacivirus/genetics ; Humans ; Male ; Recombinant Proteins/pharmacology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b.
Autorzy :
Rallón NI; Infectious Diseases Department, Hospital Carlos III, Madrid, Spain.
Pineda JA
Soriano V
Neukam K
Vispo E
Rivero A
Labarga P
Caruz A
Restrepo C
Camacho A
Barreiro P
Benito JM
Pokaż więcej
Źródło :
Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2012 Jun 01; Vol. 60 (2), pp. 117-23.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*administration & dosage
HIV Infections/*complications
Hepacivirus/*classification
Hepatitis C, Chronic/*complications
Hepatitis C, Chronic/*drug therapy
Interferon-alpha/*administration & dosage
Polyethylene Glycols/*administration & dosage
Ribavirin/*administration & dosage
Adult ; Female ; Genotype ; Hepacivirus/genetics ; Hepacivirus/isolation & purification ; Hepatitis C, Chronic/virology ; Humans ; Male ; Middle Aged ; Recombinant Proteins/administration & dosage ; Retrospective Studies ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.
Autorzy :
Neukam K; Unit of Infectious Diseases and Microbiology, Hospital Universitario de Valme, Seville, Spain.
Camacho A
Caruz A
Rallón N
Torres-Cornejo A
Rockstroh JK
Macías J
Rivero A
Benito JM
López-Cortés LF
Nattermann J
Gómez-Mateos J
Soriano V
Pineda JA
Pokaż więcej
Źródło :
Journal of hepatology [J Hepatol] 2012 Apr; Vol. 56 (4), pp. 788-94. Date of Electronic Publication: 2011 Dec 13.
Typ publikacji :
Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Algorithms*
HIV Infections/*drug therapy
Hepacivirus/*genetics
Hepatitis C/*drug therapy
Interferon-alpha/*therapeutic use
Interleukins/*genetics
Polyethylene Glycols/*therapeutic use
RNA, Viral/*blood
Ribavirin/*therapeutic use
Adult ; Antiviral Agents/therapeutic use ; Cohort Studies ; Comorbidity ; Drug Therapy, Combination ; Female ; Genotype ; HIV Infections/epidemiology ; Hepatitis C/epidemiology ; Humans ; Interferon alpha-2 ; Interferons ; Male ; Middle Aged ; Models, Statistical ; Prospective Studies ; Recombinant Proteins/therapeutic use ; Regression Analysis ; Retrospective Studies ; Treatment Outcome ; Viral Load
Czasopismo naukowe
Tytuł :
Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4.
Autorzy :
Rivero-Juárez A; Infectious Diseases Unit, Maimonides Institute for Biomedical Research (IMIBIC), University Hospital Reina Sofia, Cordoba, Spain.
Camacho Espejo A
Perez-Camacho I
Neukam K
Caruz A
Mira JA
Mesa P
García-Lázaro M
Torre-Cisneros J
Pineda JA
Rivero A
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2012 Jan; Vol. 67 (1), pp. 202-5. Date of Electronic Publication: 2011 Oct 11.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Viral Load*
Antiviral Agents/*administration & dosage
Hepacivirus/*isolation & purification
Hepatitis C/*genetics
Interferons/*administration & dosage
Interleukins/*genetics
Ribavirin/*administration & dosage
Adult ; Drug Therapy, Combination/methods ; Female ; Genotype ; HIV Infections/complications ; Hepatitis C/complications ; Hepatitis C/drug therapy ; Hepatitis C/virology ; Humans ; Male ; Plasma/virology ; Prospective Studies ; RNA, Viral/blood ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patients.
Autorzy :
Rivero-Juárez A; Unit of Infectious Diseases, Hospital Universitario Reina Sofia, Cordoba, Spain.
Lopez-Cortes LF
Camacho A
Torres-Cornejo A
Pineda JA
Marquez-Solero M
Caruz A
Ruiz-Valderas R
Torre-Cisneros J
Gutierrez-Valencia A
Rivero A
Pokaż więcej
Źródło :
PloS one [PLoS One] 2012; Vol. 7 (11), pp. e48959. Date of Electronic Publication: 2012 Nov 08.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*therapeutic use
HIV/*growth & development
HIV Infections/*drug therapy
Hepacivirus/*growth & development
Hepatitis C/*drug therapy
Interferon-alpha/*administration & dosage
Polyethylene Glycols/*administration & dosage
Ribavirin/*administration & dosage
Adult ; Coinfection/drug therapy ; Coinfection/genetics ; Dose-Response Relationship, Drug ; Drug Therapy, Combination/methods ; Female ; Genotype ; HIV/genetics ; HIV Infections/blood ; HIV Infections/genetics ; HIV Infections/virology ; Hepacivirus/genetics ; Hepatitis C/blood ; Hepatitis C/genetics ; Hepatitis C/virology ; Humans ; Male ; Prospective Studies ; Recombinant Proteins/administration & dosage ; Treatment Outcome ; Viral Load/drug effects
Czasopismo naukowe
Tytuł :
Twelve week post-treatment follow-up predicts sustained virological response to pegylated interferon and ribavirin therapy in HIV/hepatitis C virus co-infected patients.
Autorzy :
Rivero-Juárez A; Infectious Diseases Unit, Maimonides Institute for Biomedical Research (IMIBIC), University Hospital Reina Sofia, Cordoba, Spain.
Mira JA
Pérez-Camacho I
Macías J
Camacho A
Neukam K
Torre-Cisneros J
Merchante N
Pineda JA
Rivero A
Pokaż więcej
Corporate Authors :
Viral Hepatitis Study Group, part of the Sociedad Andaluza de Enfermedades Infecciosas (SAEI) (Andalusian Society for Infectious Diseases)
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2011 Jun; Vol. 66 (6), pp. 1351-3. Date of Electronic Publication: 2011 Mar 17.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Therapy, Combination/*methods
HIV Infections/*complications
Hepatitis C/*complications
Hepatitis C/*drug therapy
Interferon-alpha/*administration & dosage
Polyethylene Glycols/*administration & dosage
Ribavirin/*administration & dosage
Adult ; Antiviral Agents/administration & dosage ; Female ; Follow-Up Studies ; Humans ; Interferon alpha-2 ; Male ; Middle Aged ; Predictive Value of Tests ; RNA, Viral/blood ; Recombinant Proteins ; Retrospective Studies ; Reverse Transcriptase Polymerase Chain Reaction/methods ; Time Factors ; Treatment Outcome ; Viral Load/methods
Czasopismo naukowe
Tytuł :
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.
Autorzy :
Labarga P; Hospital Carlos III, Madrid, Spain.
Barreiro P
Mira JA
Vispo E
Rallón N
Neukam K
Camacho A
Caruz A
Rodriguez-Novoa S
Pinilla J
Rivero A
Benito JM
Pineda JA
Soriano V
Pokaż więcej
Źródło :
AIDS (London, England) [AIDS] 2011 May 15; Vol. 25 (8), pp. 1131-3.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Polymorphism, Genetic*/genetics
AIDS-Related Opportunistic Infections/*drug therapy
Antiviral Agents/*administration & dosage
HIV Infections/*drug therapy
Hepatitis C, Chronic/*drug therapy
Interferon-alpha/*administration & dosage
Polyethylene Glycols/*administration & dosage
Ribavirin/*administration & dosage
AIDS-Related Opportunistic Infections/genetics ; Adult ; Drug Therapy, Combination ; Female ; HIV Infections/genetics ; Hepatitis C, Chronic/genetics ; Humans ; Interferon alpha-2 ; Male ; Recombinant Proteins ; Recurrence
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies